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Abstract
Introduction:ToF patients are at risk for ventricular deterioration at a relatively young age, which
canbe aggravatedbyAFdevelopment. Therefore, knowledgeonAFdevelopment and its timespan
of progression is essential to guide treatment strategies for AF.
Objective:Weexamined late postoperative AF onset and progression in ToF patients during long-
term follow-up after ToF correction. In addition, coexistence of AF with regular supraventricular
tachyarrhythmias (SVT) and ventricular tachyarrhythmias (VTA) was analyzed.
Methods and results: ToF patients (N = 29) with AF after ToF correction referred to the electro-
physiology department between 2000 and 2015were included. All available rhythm registrations
were reviewed for AF, regular SVT, andVTA. AF progressionwas defined as transition fromparox-
ysmal AF to (longstanding) persistent/permanent AF or from (longstanding) persistent AF to per-
manent AF. At the age of 44 ± 12 years, ToF patients presented with paroxysmal (N = 14, 48%),
persistent (N = 13, 45%) or permanentAF (N = 2, 7%). Age ofAFdevelopmentwas similar among
patients who either underwent initial shunt creation (N = 15, 45 ± 11 [25–57] years) or primary
total ToF correction (N = 14, 43 ± 13 [26–66] years) (P = 0.785). AF coexisted with regular SVT
(N = 18, 62%) and VTA (N = 13, 45%). Progression of AF occurred in 11 patients (38%) within 5
± 5 years after AF onset despite antiarrhythmic drug class II (AAD, P = 0.052) or III (P = 0.587)
usage.
Conclusions: AF in our ToF population developed at a young age and showed rapid progression.
Rhythm control by pharmacological therapy was ineffective in preventing AF progression.
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1 INTRODUCTION
Tetralogyof Fallot (ToF) is themost prevalent cyanotic congenital heart
disease (CHD);1 approximately 4% of all patients with CHD are diag-
nosed with ToF.2 As a result of improved medical care and advances in
surgical techniques since the1950s,more than85%of theToFpatients
nowadays survive into adulthood.1
However, new challenges arose since long-term complications, such
as tachyarrhythmias, became more prevalent. In the registry of the
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Alliance for Adult Research in Congenital Cardiology (AARCC), up to
43% of the 556 ToF patients had tachyarrhythmias.3
In previous studies, ventricular tachyarrhythmias (VTA)with poten-
tially devastating consequences were frequently observed.4,5 How-
ever, the prevalence of supraventricular tachyarrhythmias (SVT) is
also considerably high.6,7 SVT were present in 20% of the patients
included in the AARCC registry; intra-atrial reentrant tachyarrhyth-
mias (IART) were most prevalent (12%) whereas 7% had atrial fibril-
lation (AF).
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The incidence of AF increases with age and is more prevalent in ToF
patients older than 55 years. The mechanism underlying AF develop-
ment in ToF patients is unknown. Previous studies identified palliative
shunting prior to total ToF correction as a predictor for SVT and AF.6
Also, it was suggested that regular SVTmight facilitate development of
AF in CHD patients.8
Due to multiple surgical procedures and often long-term pres-
sure and volume overload, ToF patients are at risk for ventricular
deterioration at a relatively young age, which can be aggravated by AF
development.9–11
Therefore, particularly in ToF patients, knowledge on AF develop-
ment and its timespan of progression is essential to guide treatment
strategies for AF. Individualized AF therapy may thereby contribute to
maximal preservation of ventricular function in these patients.
The aims of this study were to examine (1) onset of AF in a cohort
of patients who underwent total ToF correction in relation to clinical
profiles and (2) progression of late, postoperative AF in ToF patients
during long-term follow-up.
2 METHODS
This retrospective longitudinal study was part of the “DysrhythmiAs
in patieNts with congenitAl heaRt diseAse” (DANARA) project (MEC-
2012-482) andwas approvedby the local ethics committee in the Eras-
mus University Medical Center Rotterdam. Informed consent was not
obliged.
2.1 Study population
All corrected ToF patients with documented AF episodes referred
to the electrophysiology department between 2000 and 2015 were
included in this study (N = 29); patients with pulmonary atresia
were excluded. Data on demographics and clinical characteristics
including, echocardiograms, cardiac surgery, prescribed antiarrhyth-
mic drugs (AAD), outcomes of electrocardioversions (ECV) or death
were retrieved from the patient medical records.
2.2 Clinical data
All rhythm registrations collected during routine visits at the outpa-
tient clinic, hospitalization, or at the emergency room including elec-
trocardiograms (ECG), 24-hour Holter registrations and device print
outs were reviewed for episodes of AF or regular SVT.
An irregular rhythm combinedwith a clear beat-to-beat variation in
the morphology of atrial waves was considered as AF. AF was catego-
rized as paroxysmal, persistent or permanent AF according to the ESC
guidelines for themanagement of AF.12
The investigators did not differentiate between a typical (counter)
clockwise atrial flutter, IARTor ectopic atrial tachycardia, as differenti-
ation between these types of SVT cannot always bemade based on the
surfaceECGonly. AFprogressionwasdefinedas transition fromparox-
ysmal AF to (longstanding) persistent/permanent AF or from (long-
standing) persistent AF to permanent AF. In addition to the occurrence
of AF and regular SVT, rhythm registrations were also reviewed for
occurrence of VTA, including nonsustained and sustained ventricular
tachycardia (nsVT, sVT) and ventricular fibrillation (VF).
ECG characteristics obtained from a standard resting ECG
(25 mm/s) included QRS duration and QT dispersion; QT interval was
measured from the onset of the QRS wave to the end of the T wave,
defined as a return to T-P baseline.Data regarding right atrial (RA)
dilation and right ventricular (RV) dysfunction were obtained from
echocardiography. RV end diastolic volumes (RVEDV) were retrieved
from cardiacMRI.
2.3 Statistical analysis
Normally distributed continuous variables were expressed as mean ±
standard deviation; skeweddatawere presented asmedian (minimum-
maximum). Student's t-test, ANOVA test, and Mann–Whitney U test
were used to compare patient groups. Categorical data were denoted
by percentages and compared with the X2 test or Fisher's exact test.
A P-value of <0.05 was considered statistically significant. Statistical
analysiswas performedwith SPSS, version 21 (IBM,Armonk,NY,USA).
3 RESULTS
3.1 Study population
The study population consisted of 29 ToF patients (18male). As shown
in Table 1, 15 patients (52%) underwent palliative shunting prior to
total ToF correction. Median age at the time of shunt creation was 4
(0.6–13) years. Total ToF correction was performed at a median age of
14 (0.6–58) years; patients with prior palliative shunt: 13 (3–58) years;
primary total ToF correction: 15 (0.5–29) years (P= 0.477). Age at last
follow-upwas 55± 12 (32–79) years.
Twenty patients (69%) demonstrated a complete right bundle
branch block (RBBB) and 2 patients had incomplete RBBB (7%). Mean
QRS duration prior to AF onset was 150 ± 38 (90–226) millisec-
onds and 7 patients (24%) had a QRS duration ≥180 milliseconds.
Mean QT-dispersion was 92 ± 42 (40–200) milliseconds. Echocardio-
graphic examination at the time of AF observation showed RA dilata-
tion (N = 19, 66%) and a mild (N = 12, 41%), moderate (N = 5, 17%) or
severe (N=7, 24%) RVdysfunction. Data regarding either atrial dilata-
tion or right ventricular function prior to AF onset was not available in
respectively 3 and 4 patients. Fifteen patients underwent cardiacMRI,
in whommean RVEDVwas 211± 89 (95–400) mL.
3.2 Onset of atrial fibrillation
The upper panel of Figure 1 illustrates age at first AF episode for each
patient individually; patients are ranked according to the age of AF
onset. Onset of AF occurred at a mean age of 44 ± 12 (25–72) years,
which was 28 ± 14 years after total ToF correction. In 1 patient, AF
occurred47years after palliative shunting, yet before undergoing total
ToF correction.
As shown in the lower panels of Figure 1, age at first AF episode
tended to decrease in more recent decades, yet this did not reach
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TABLE 1 Patient characteristics
Population (N) 29
Male gender (N [%]) 18 (62)
Prior palliative shunt 15 (52)
Age palliative shunt 4 (0.6–13)
Age total ToF correction 14 (0.6–58)
Age first AF episode 44± 12 (25–72)
Age last follow-up 55± 12 (32–79)
AF onset N (%)
Paroxysmal 14 (48)
Persistent 13 (45)
Permanent 2 (7)
Right bundle branch blocka
Complete 20 (69)
Incomplete 2 (7)
QRS duration (milliseconds)a 150± 38 (90–226)
≥180milliseconds 7 (24)
QT dispersion 92± 42 (40–200)
RA dilationa 19 (66)
RV end diastolic volumea 211± 89 (95–400)
RVF*
Normal 1 (3)
Mild dysfunction 12 (41)
Moderate dysfunction 5 (17)
Severe dysfunction 7 (24)
aMissing clinical data:QRSduration (4), RAdilation (3), RVF (4), cardiacMRI
RVEDV(14).
RA = right atrium; RVF = right ventricular function; MRI =magnetic reso-
nance imaging; RVEDV= right ventricular end-diastolic volume.
statistical significance (P = 0.063). Time interval from total ToF onset
to first AF episode, however, was significantly shorter in more recent
decades of surgical management (P= 0.005).
The first AF episode was paroxysmal (N = 14, 48%), persistent
(N = 13, 45%) or permanent (N = 2, 7%); therapy consisted of only
rate control in 2 patients presenting with persistent AF and they were
therefore labeled as having permanent AF.
We subdivided the study population into two groups; patient who
underwent prior palliative shunting followed by total ToF correction
and patients who underwent primary total ToF correction.
At first presentation of AF, the incidence of RA dilation did not dif-
fer between patients without andwith palliative shunting (N= 9 [64%]
vs. N = 10 [67%], respectively, P = 0.893). Also, no difference was
observed in the incidenceofmoderate or severeRVdysfunction (N=7,
50% vs. N= 6, 40%, respectively, P= 0.588).
As illustrated in the left panel of Figure 2, patients who underwent
prior palliative shunting developed AF at the same age as patients who
underwent initial ToF correction, respectively, at 45 ± 11 (25–57) and
43± 13 (26–66) years (P= 0.785). Time interval from total ToF correc-
tion to onset of AF also was similar between patients without andwith
prior palliative shunting (30 ± 10 [10–46] and 27 ± 15 [0–47] years,
respectively, P= 0.544).
F IGURE 1 Age distribution at AF onset. Upper panel: Age at first
AF episode for every individual patient is demonstrated. Lower panels:
Age at first AF episode and interval from total ToF correction to first
AF episode according to decade of total ToF correction
3.3 Coexistence of atrial and ventricular
tachyarrhythmias
As shown in the left panel of Figure 3, coexistence of AF and regular
SVT was reported in 18 patients (62%), in whom SVT most often pre-
sented prior to AF (N = 13, 76%; 10 ± 12 years prior). In 3 patients,
episodes of both regular SVT and AF were documented in the same
year. In 2 patients, SVT presented, respectively, 6 and 22 years after
onset of AF. A total of 4 patients underwent catheter ablation for SVT.
In 2 patients, SVTablationwas performed, respectively, 1 and1.6 years
prior to AF onset, whereas in the other 2 patients SVT ablation was
performed, respectively, 1 and 25 years after the first documented AF
episode.
The right panel of Figure 3 summarizes the presence of the differ-
ent types of VTA. VTA occurred in 13 patients, including non-sustained
VT (N = 5), sustained VT (N = 5) and out-of-hospital cardiac arrest
(N = 3). Nonsustained VTA occurred prior to AF in 1 patient, years
after onset of AF in 2 patients and within the same year as AF onset
in 2 patients. Sustained VTA occurred prior to AF in 3 patients, years
after AF in 1 patient and within the same year in one patient. All
OHCA (VF) occurred years prior to AF development. Two patients
underwent ablation of VT, respectively, 11 and 14 years prior to the
first documented AF episode. Patients with VTA more often showed
QRS duration ≥180 (N = 6, 55%) compared to patients without
VTA (N = 1, 7%; P = 0.021). QT dispersion was similar between
patients without and with VTA (98 ± 37 and 85 ± 47, respectively,
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F IGURE 2 Differences in AF onset. Left panel: Age at AF onset in patients without and with prior palliative shunting. Right panel: Time interval
from total ToF correction to AF onset in patients without andwith prior palliative shunting
F IGURE 3 Atrial and ventricular tachyarrhythmias. Left panel: Incidence of patients with only AF and with coexistence of regular SVT and AF.
Right panel: IncidenceofVTA, includingnonsustainedVT, sustainedVT, andVF.AF= atrial fibrillation; SVT= regular supraventricular tachyarrhyth-
mia; VTA = ventricular tachyarrhythmia; nsVT = nonsustained ventricular tachycardia; sVT = sustained ventricular tachycardia; VF = ventricular
fibrillation
P = 0.417), as well as RVEDV (197 ± 54 vs. 232 ± 128, respectively;
P= 0.469).
3.4 Progression of atrial fibrillation
Treatment of AF and rhythm outcome after long-term follow-up is
summarized in Figure 4; the study population was subdivided accord-
ing to the initial type of AF.
The majority of patients with paroxysmal AF (N = 14) were treated
with AAD (N = 13, 93%), which was aimed at rhythm control in
7 patients (54%); one patient did not receive any pharmacological
treatment. Two patients with paroxysmal AF underwent ECV.
Of the 13 patients with persistent AF, 7 patients (54%) were ini-
tially cardioverted, of whom 6 patients (85%) started AAD after ECV.
For theother6patients (46%), initial treatment consistedofAAD, after
which ECVwas performed in 3 patients (50%). Of the 12 patients with
persistent AF receiving AAD, treatment with AAD was aimed at
rhythm control in 8 patients (67%). Two patients presented with per-
manent AF, as only rate control therapy was initiated and no attempts
to cardioversionwere performed.None of the patients underwent pul-
monary vein isolation or his bundle ablation.
Progression of AF was observed in 11 patients (38%), which
occurred 5 ± 5 (0.02–18) years after the first AF episode. Age at AF
progressionwas 45± 10 (31–59) years. As shown in the upper panel of
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F IGURE 4 Atrial fibrillation therapy and progression flowchart providing an overviewof the initial AF therapy and long-termoutcome. The study
populationwas subdivided according the type ofAF at the initialmoment of presentation. A detailed explanation is provided in paragraph “progres-
sion of atrial fibrillation.” AAD= antiarrhythmic drugs; AF= atrial fibrillation; ECV= electrocardioversion
F IGURE 5 Upper panel: Incidence of AF progression and differences in use of antiarrhythmic drugs between patients without andwith progres-
sion. Lower panels: Ranked timespans of AF progression for each patient with progression (left) and overview of number of patients and average
timespan for each type of AF progression (right)
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Figure 5, there was no difference in general AAD usage between
patients without and with AF progression. Amiodarone was used by
7 (39%) of the 18 patients without progression and 3 (27%) of the
11 patients with progression (P= 0.694).
The lower panels of Figure 5 illustrate the time period required for
AF progression (left panel) and transition between the different types
of AF (right panel). Progression of paroxysmal AF (N = 14, 48%) to
either persistentAF (N=1, 7%)or permanentAF (N=4, 29%)occurred
within respectively 2 and 5 ± 3 (2–8) years. Of the 13 patients (45%)
who initially presentedwith persistentAF, 6 patients (46%) progressed
to permanent AFwithin 5± 7 (0.02–18) years.
3.5 Mortality
Follow-up time from first AF episode was 11 ± 9 (1–39) years. A total
of 10 patients (35%) died at a mean age of 56 ± 11 (33–75) years and
9 ± 8 (1–27)years after AF onset. Nine patients died due to end stage
heart failure (age 59 ± 8 years) and 1 patient died due to a shooting
incident (age 33 years).
There was no difference in incidence of death between patients
without andwith prior palliative shunting (N= 4 [29%] vs. N= 6 [40%],
respectively, P = 0.700), nor in age of death (51 ± 13 [33–63] years vs.
60± 9 [52–75] years, respectively, P= 0. 216)
Incidenceof deathwas the samebetweenpatientswithout andwith
AF progression (N= 6 [33%] vs. N= 4 [36%], respectively, P= 1.00), as
well as age of death (54 ± 11 [33–64] years vs. 59 ± 11 [51–75] years,
respectively, P= 0.470).
4 DISCUSSION
This study reports on development and progression of postopera-
tive AF over time in patients with ToF. AF in ToF patients is often a
progressive disease at a relatively young age and both rhythm-control
and rate-control therapy were equally ineffective in preventing this.
Coexistence of AF with other tachyarrhythmias, including regular SVT
or VTwas observed in themajority of the study population.
4.1 Age of atrial fibrillation onset
A steep rise in the prevalence of AF from the age of 45 years in ToF
patients was demonstrated by Khairy et al., which is comparable with
themean age of AF onset in our study population.3
It is generally assumed that perpetuation of AF is facilitated by
areas of intra-atrial conduction delay or dispersion in refractoriness
that has been demonstrated in mapping studies in patients without
CHD.13–15 Prior electrophysiological studies in CHD patients demon-
strated that areas of intra-atrial conduction delay or dispersion in
refractoriness are also present in patients with complex CHD.16 In
these patients, intra-atrial conduction is impaired by interposition of
fibrotic tissue caused by surgical procedures and ongoing pressure or
volume overload.17 In addition, triggered activity might be increased
by enhanced atrial wall stress.
Previous studies have identified palliative shunting as a predictor
for SVT or AF,6 yet we did not observe a difference in age at AF onset
between patients undergoing prior palliative shunting versus total ToF
correction.
In our population, approximately half of the patients underwent
prior palliative shunting and were thereby longer exposed to the
consequences of their cardiac defect, awaiting total ToF correction.
Although impairment of cardiac function was indeed observed in our
study population, prior palliative shunting did not influence incidences
of ventricular dysfunction.
At present, the optimal age for ToF correction is between the age
of 3 and 6 months old.18 Our patient population consists of a sub-
set of the patients who were operated on in the early days of cardiac
surgery and is actually presenting the long-term present-day compli-
cations of corrective surgery for ToF patients operated some decades
ago. In our population, total ToF correction was performed on average
40 years ago. Patients who underwent total ToF correction more
recently tended to develop AF earlier after corrective surgery, which
may be explained by improved and more standardized methods of
follow-up and AF detection.
4.2 Coexistence of tachyarrhythmias
In more than 60% of the study population, AF coexisted with regular
SVT, which is much higher compared to the 33% that was reported
in an earlier study with 199 patients with various CHD and AF.8 This
observation suggests thatToFpatients aremoreprone todevelopment
of regular SVT compared to patients with other CHD. Although this
is not uniformly confirmed,19 a number of studies indeed reported a
high prevalence of regular SVT in ToF patients.3,20 Mah et al. identi-
fied intra-atrial reentry as the primary mechanism of regular SVT in
53 ToF patients; reentrant circuits involved predominantly the cavotri-
cuspid isthmus and areas of post-surgical scarring in the lateral wall
of the RA.21 The majority of the patients in our study population pre-
sented with regular SVT prior to AF onset. This observation could
be explained by shortening of atrial refractoriness and inverse rate
adaptation induced by regular SVT, thereby facilitating development
of AF.22,23 However, some patients initially presented with AF, which
could be explained by alternating episodes of SVT and AF due to insta-
bility of a functional line of conduction block between the caval veins
required for establishing a macroreentrant circuit.24,25 Furthermore,
earlier, asymptomatic transient episodes of AF or regular SVT could
have beenmissed.
VTA coexisted with AF in a considerable number of patients in our
study population. A previous study demonstrated that AF might facili-
tate the onset of VTA. When AF activates the ventricles at a high rate,
ventricular refractoriness is shortened, which in turn promotes onset
of VTA.26 Denker et al. described that short-long-short sequences
caused by AF, might be proarrhythmic and facilitates VTA onset.27
Somberg et al. showed that induction of VTA by programmed electri-
cal stimulation in canine ventricles only induced VTA (96%) during AF
and not during sinus rhythm, also supporting the concept that AF facil-
itates development of VTA.28
36 RAMDJAN ET AL.
Four patients in this study developed nsVT or sVT prior to AF onset
and all OHCA occurred prior to AF development. It is known that
long-term hypoxemia in ToF patients, in addition to the ongoing pres-
sure/volume overload, contributes to degeneration of cardiomyocytes
and interstitial fibrosis,which in turn give rise toonset ofVTA.29Devel-
opment of AF several years after VTA onset may be an indicator of fur-
ther hemodynamic deterioration.
4.3 Progression of atrial fibrillation
In our study population, AF progressed in a considerable number of
patients within a short period of time; progression of AF occurred at
a mean age of 44 years and only 5 years after the first documented
episode. In the European Heart Survey, progression of AF was more
frequently observed in patients who presented with AF at an older
age.30 Older age at the moment when patients first present with AF
may therefore also influence rate of progression of AF. Also, it has been
demonstrated that electrical and structural remodeling contribute to
persistence of AF.31 Chronic atrial stretch caused by either persistent
pressure or volume overload in CHD patients may additionally con-
tribute topersistenceof electrical and structural remodeling.32 InCHD
patients, substrate mapping of the atria may be of particular interest
to establish the pathophysiologic basis of arrhythmias. In ToF patients,
the atria are often hyperthrophied and has extensive fibrotic regions
enabling multiple reentrant circuits to occur. Often, during ablation,
one tachycardia will convert to a different tachycardia indicated by
changes in cycle length or patterns of activation.33 Optimal assess-
ment and treatment of SVT in ToF and other CHD patients there-
fore requires a stepwise approach to confirm involvement of particular
anatomical areas by entrainment and detailed mapping of the reentry
circuit and critical isthmus. In ToF patients, commonly identified cir-
cuits include the sub-Eustachian isthmus between the tricuspid valve
annulus and inferior vena cavaand theposterolateral right atriumadja-
cent to the atriotomy incision.33 However, when the critical isthmus
cannot be defined properly by entrainment and activation mapping,
it has been suggested that identifying low voltage areas, indicating
extensive atrial scarring and sites of surgical incisions, could be used
as an alternative approach.33 When creating a linear lesion between
scar tissue and anatomical obstacles such as valve annuli, SVT may be
eliminated.33
Similar approaches can also be used to treat VT in ToF patients.34
Often, VT in ToF patients are related to the scar site of the ventriculo-
tomyand theuseof a transannular patch for reconstructionof the right
ventricular outflow tract. Prior studies have demonstrated that critical
isthmuses are located between (1) the right ventricular outflow tract
patch or ventriculotomy scar and the tricuspid annulus; (2) the right
ventriculotomy scar and the pulmonary valve; (3) the ventricular sep-
tal defect patch and the pulmonary valve; and (4) the ventricular septal
defect patch to the tricuspid valve.34
4.4 Effectiveness of pharmacological therapy
As mentioned previously, almost 40% of our study population showed
progression of AF, which was not affected by the usage of class II
or III AAD. As class III AAD are aimed at maintaining sinus rhythm,
whereas rate control is aimed at reduction of ventricular rate during
AF episodes, AF induced remodeling is more likely to occur in patients
with only rate control therapy. In patients without CHD, it has been
demonstrated that AF episodes induce shortening of the atrial refrac-
toryperiod (ARP) and inversed rate adaptation thereby facilitatingper-
petuation of AF.35 In addition, it has been shown that effectiveness
of AAD and ECV for paroxysmal AF decreases over time, also indicat-
ing that the presence of AF episodes promote development of longer-
lasting AF episodes and hence progressiveness of AF.36,37 Atrial extra
systoles in the presence of a shorter ARP makes the patient more vul-
nerable to induction of AF episodes and hence AF progression.
5 LIMITATIONS
Our study population came into treatment decades ago according to
the surgical strategies of that time. The present day approaches will
probably lead to different findings. As the onset of AF was defined as
the first documented AF episode on an ECG, 24-hour Holter record-
ing or medical correspondence, earlier, asymptomatic episodes of
AF could have been missed. Since our study population was rela-
tively small, larger multicenter studies are necessary to confirm these
observations.
6 CONCLUSIONS
ToF patients in our study population developed AF in the 4th and
5th decade of life, which did not differ between patients who under-
went initial shunt creation or ToF correction. AF in this population is a
rapid progressive disease despite usage of AAD therapy. Coexistence
of AF with other tachyarrhythmias, including regular SVT or VTA was
observed in a major part of the study population and is most likely
the result of SVT-induced electrical and structural remodeling. Hence,
besides treatment of residual defects, early catheter ablation of SVT
may be essential in developing AF prevention strategies in this particu-
lar patient group.
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